← SynDRA
TOFACITINIB
SynDRA canonical compound SYN0006517 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | JAK3 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
| Indication | rheumatoid arthritis |
|---|
| Disease area | rheumatology |
|---|
All known targets
- JAK3
- JAK2
- JAK1
- TYK2
- ABL1
- RET
- NUAK2
- PKN1
- PKN2
- PRKCA
- PRKCD
- ROCK1
Mechanisms of action (all sources)
- JAK inhibitor
- JAK3 INHIBITOR
- Janus Kinase (JAK) inhibitor
- JAK1 INHIBITOR
- JAK2 INHIBITOR
- TYK2 INHIBITOR
- JAK3 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- TBK1
- TRPM6
- YES1
- KDR
- SYK
- PAK4
- PAICS
- PAK1
- PAK2
- PAK3
- AAK1
- PAK5
- OXSR1
- PASK
- PDE3A
- PDE4D
- PDGFRA
- PAK6
- OPRK1
- OPRM1
- OPRD1
- OPA1
- OGG1
- NUAK1
- NTSR1
- NTRK3
- NTRK2
- NTRK1
- NTHL1
- NR3C1
- NQO2
- NPY2R
- NPY1R
- PDGFRB
- PDPK1
- PDK1
- NIM1K
- PRKAA2
- PRKAA1
- PLK4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- HLA-B
- HLAB
- IFNB1
- KS6A2
- KS6A6
- KSYK
- NSD2
Drug classes
- Enzyme Inhibitors
- Janus Kinase Inhibitors
- Protein Kinase Inhibitors
- Janus Kinase Inhibitor
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- TOFACITINIB CITRATE
- XELJANZ
- XELJANZ XR
- Xeljanz
- tasocitinib
- xeljanz
- CP-690550
- tofacitinib citrate
- CP-690 FREE BASE
- 550
- CP-690-550
- CP-690
- CP-690,550
- CP-690,550 FREE BASE
- CP-690550 FREE BASE
- CP-690550-10
- CP690,550
- CP690550
- PFE-PKIS 25
- PFE-PKIS_25
- TASOCITINIB
- TASOCITINIB CITRATE
- TOFACITINIB (CONTROLLED RELEASE)
- TOFACITINIB (CP-690550)
- Tofacitinib citrate
- Tasocitinib
- CP 690550
- racemic-tofacitinib
- tofacitinibum
- UNII-87LA6FU830
- Tofacitinib (CP-690550,Tasocitinib)
- CHEMBL221959
- CHEBI:71200
- Xeljanz (TN)
- cp-690,550
- CP- 690 550
- (+)-TOFACITINIB
- Cp-690 free base
Look up TOFACITINIB in the interactive SynDRA portal →